Blueprint Medicines Investor Relations Material
Latest events
Q3 2023
Blueprint Medicines
Access the full event backlog
Slides, Transcripts, and Reports from over 8,000 public companies
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. It focuses on the discovery, development, and commercialization of small molecule therapies for patients with diseases caused by genetic mutations. The company's pipeline products include, among other, BPX-501 that targets Caskin 1; BPX-701 that is involved in targeting patients with Ras (RAS) inhibitor-refractory or -intolerant melanoma; BPX-601 that is involved in targeting basal cell carcinoma; BPX-302 that targets Bcr/Abl fusion proteins; and BPX-401 that targets NY-ESO-1.
Key slides for Blueprint Medicines Corp
Q3 2023
Blueprint Medicines Corp
Q3 2023
Blueprint Medicines Corp
Latest articles
NIBE: Creating Millionaires and a Greener Future
NIBE, just like IKEA, was founded in a rural part of Sweden called Småland. The company offers a wide range of pumps, wood stoves, and solar panels.
6 Dec 2023
The Story of Jensen Huang and Nvidia
When looking at NVIDIA’s Jensen Huang today, it is easy to stereotype him as your archetypical big tech CEO. He doesn’t wear suits like a Wall Street Chairman, instead opting to wear his now-iconic leather jackets and casual polo shirts.
6 Dec 2023
Neglect of Probability: A Hidden Risk in Decision Making
The concept of "probability" should take center stage in our decision-making processes.
4 Dec 2023
Ticker symbol
BPMC
Country
🇺🇸 United States